Lisa Hawver

Lisa Hawver is a seasoned intellectual property professional with extensive experience in the life sciences sector. Currently serving as Director of Intellectual Property at Foghorn Therapeutics Inc. since January 2022, Lisa specializes in small molecules in oncology indications and is involved in managing collaborations with Eli Lilly while maintaining organizational research integrity. Prior to this role, Lisa held positions including Associate Director of Intellectual Property at Acceleron Pharma, where oversight of over forty patent families in biologics related to pulmonary and renal indications was provided. Additionally, experience as a Patent Agent at Choate, Hall & Stewart LLP involved guiding clients through global patent protections for diverse technologies, while earlier roles included scientific research and technology transfer at Tufts University and a Ph.D. in Chemistry/Biochemistry from Northeastern University.